Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | CES2 | O00748 | 4/20 | 0.34 |
| ▸ | CES1 | P23141 | 4/20 | 0.34 |
| ▸ | GCGR | P47871 | 8/20 | 0.34 |
| ▸ | CA12 | O43570 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | CA9 | Q16790 | 1/20 | 0.33 |
| ▸ | ERN1 | O75460 | 1/20 | 0.32 |
| ▸ | PDE2A | O00408 | 1/20 | 0.31 |
| ▸ | RAPGEF4 | Q8WZA2 | 1/20 | 0.31 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23212715 | 1.00 | MEN1 (0.41) | MEN1KMT2ACES2CES1GCGR | |
| SCHEMBL22728416 | 0.86 | MEN1 (0.37) | MEN1KMT2ACES2CES1GCGR | |
| SCHEMBL29921092 | 0.84 | KMT2A (0.36) | MEN1KMT2ACES2CES1GCGR | |
| SCHEMBL23834717 | 0.84 | KMT2A (0.36) | MEN1KMT2ACES2CES1GCGR | |
| SCHEMBL1349867 | 0.80 | GABRA1 (0.38) | MEN1KMT2A | |
| SCHEMBL2144930 | 0.80 | GABRA1 (0.38) | MEN1KMT2A | |
| SCHEMBL12819965 | 0.80 | CES2 (0.32) | MEN1KMT2ACES2CES1CA12 | |
| SCHEMBL27248110 | 0.80 | GABRA1 (0.38) | MEN1KMT2AGCGRPDE2A | |
| SCHEMBL2093717 | 0.78 | CES2 (0.37) | CES2CES1CA12CA1CA9 | |
| SCHEMBL8277424 | 0.78 | RAPGEF4 (0.33) | CES2CES1CA12CA1CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8952083-B2 | Fluorocopolymer composition and its production process | ASAHI GLASS COMPANY, LIMITED (JP) | 2015-02-10 | — | — | US | claimed |
| EP-4041727-B1 | ATF6 MODULATORS AND USES THEREOF | ALTOS LABS INC (US) | 2026-05-20 | — | — | EP | disclosed |
| CN-119823112-A | ATF6 modulators and uses thereof | 阿尔托斯实验室公司 | 2025-04-15 | — | — | CN | disclosed |
| CN-115135645-B | ATF6 modulators and uses thereof | 阿尔托斯实验室公司 | 2024-12-27 | — | — | CN | disclosed |
| US-20220389001-A1 | ATF6 MODULATORS AND USES THEREOF | ALTOS LABS, INC. | 2022-12-08 | — | — | US | disclosed |
| US-20220389001-A1 | ATF6 MODULATORS AND USES THEREOF | ALTOS LABS, INC. | 2022-12-08 | — | — | US | disclosed |
| US-20220332699-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS OF USE | SAGE THERAPEUTICS, INC. | 2022-10-20 | — | — | US | disclosed |
| CN-115135645-A | ATF6 modulators and uses thereof | 普拉西斯生物技术有限责任公司 | 2022-09-30 | — | — | CN | disclosed |
| EP-4041727-A1 | ATF6 MODULATORS AND USES THEREOF | Praxis Biotech LLC (US) | 2022-08-17 | — | — | EP | disclosed |
| EP-3976186-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS OF USE | Sage Therapeutics, Inc. (US) | 2022-04-06 | — | — | EP | disclosed |
| WO-2020243027-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS OF USE | SAGE THERAPEUTICS, INC. (US) | 2020-12-03 | — | — | WO | disclosed |
| US-9663508-B2 | Biaryl acyl-sulfonamide compounds as sodium channel inhibitors | AMGEN INC. (US) | 2017-05-30 | — | — | US | disclosed |
| US-9663508-B2 | Biaryl acyl-sulfonamide compounds as sodium channel inhibitors | AMGEN INC. (US) | 2017-05-30 | — | — | US | disclosed |
| US-20160214971-A1 | Biaryl Acyl-Sulfonamide Compounds as Sodium Channel Inhibitors | One Amgen Center Drive (US) | 2016-07-28 | — | — | US | disclosed |
| US-20160214971-A1 | Biaryl Acyl-Sulfonamide Compounds as Sodium Channel Inhibitors | One Amgen Center Drive (US) | 2016-07-28 | — | — | US | disclosed |
| US-8952083-B2 | Fluorocopolymer composition and its production process | ASAHI GLASS COMPANY, LIMITED (JP) | 2015-02-10 | — | — | US | disclosed |
| CN-102186921-B | Fluorine-containing copolymer composition and process for production thereof | ASAHI GLASS CO LTD | 2014-01-15 | — | — | CN | disclosed |
| EP-2338935-B1 | FLUORINE-CONTAINING COPOLYMER COMPOSITION AND PROCESS FOR PRODUCTION THEREOF | ASAHI GLASS CO LTD (JP) | 2012-12-12 | — | — | EP | disclosed |
| US-20110172336-A1 | FLUOROCOPOLYMER COMPOSITION AND ITS PRODUCTION PROCESS | ASAHI GLASS COMPANY, LIMITED (JP) | 2011-07-14 | — | — | US | disclosed |
| EP-2338935-A1 | FLUORINE-CONTAINING COPOLYMER COMPOSITION AND PROCESS FOR PRODUCTION THEREOF | ASAHI GLASS COMPANY, LIMITED (JP) | 2011-06-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160214971-A1 | Biaryl Acyl-Sulfonamide Compounds as Sodium Channel Inhibitors | SCN1A, SCN1B, SCN5A | MEN1 3534/4885KMT2A 1504/4885CES2 791/4885 |
| US-20220389001-A1 | ATF6 MODULATORS AND USES THEREOF | ATF4, XBP1, ATF1 | MEN1 4368/4885KMT2A 4077/4885CES2 2900/4885 |
| US-20220332699-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS OF USE | CYP46A1, CYP26A1, CYP21A2 | MEN1 3333/4885KMT2A 1726/4885CES2 111/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.